Windtree Therapeutics, a biotech firm based in Pennsylvania and listed on the Nasdaq under the ticker WINT, has announced plans to purchase up to $700 million in BNB cryptocurrency. This move follows the asset's recent all-time high of $808. The company is raising $520 million to finance these purchases, in addition to its previously announced $200 million plan. Windtree will partner with crypto exchange Kraken for custody services. The funding will come from a $500 million equity line of credit with an unspecified institutional investor and a separate $20 million stock purchase agreement with Build and Build Corp. CEO Jed Latkin emphasized the importance of securing additional funds for these BNB purchases as part of the company's strategic approach. BNB, the fifth-largest digital coin by market cap, is seeing increased interest from publicly traded firms as more companies adopt crypto treasuries. Windtree's stock saw a significant rise of 162% over the past month, despite a recent 5% decline. Other companies, like Nano Labs, are also looking to acquire substantial amounts of BNB, indicating a growing trend among institutional investors.

Source 🔗